165 related articles for article (PubMed ID: 23269785)
1. A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.
Cobleigh MA; Wei X; Robek MD
J Virol; 2013 Mar; 87(5):2969-73. PubMed ID: 23269785
[TBL] [Abstract][Full Text] [Related]
2. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
3. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
[TBL] [Abstract][Full Text] [Related]
4. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.
Cobleigh MA; Bradfield C; Liu Y; Mehta A; Robek MD
J Virol; 2012 Apr; 86(8):4253-61. PubMed ID: 22345454
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8
Chiale C; Moshkani S; Rose JK; Robek MD
Antiviral Res; 2019 Aug; 168():156-167. PubMed ID: 31153968
[TBL] [Abstract][Full Text] [Related]
6. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.
Cobleigh MA; Buonocore L; Uprichard SL; Rose JK; Robek MD
J Virol; 2010 Aug; 84(15):7513-22. PubMed ID: 20504927
[TBL] [Abstract][Full Text] [Related]
7. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
8. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.
Loirat D; Lemonnier FA; Michel ML
J Immunol; 2000 Oct; 165(8):4748-55. PubMed ID: 11035120
[TBL] [Abstract][Full Text] [Related]
9. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
Oka Y; Akbar SM; Horiike N; Joko K; Onji M
Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
11. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
[TBL] [Abstract][Full Text] [Related]
12. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
[TBL] [Abstract][Full Text] [Related]
13. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization.
Mancini M; Hadchouel M; Tiollais P; Michel ML
J Immunol; 1998 Nov; 161(10):5564-70. PubMed ID: 9820533
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
15. A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.
Zhang Y; Su WJ; Wang J; Bai XF; Huang CX; Lian JQ
Viral Immunol; 2014 Nov; 27(9):430-7. PubMed ID: 25211639
[TBL] [Abstract][Full Text] [Related]
16. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells.
Roh S; Kim K
Microbiol Immunol; 2003; 47(6):453-60. PubMed ID: 12906106
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
[TBL] [Abstract][Full Text] [Related]
18. Nasal route favors the induction of CD4
Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
[TBL] [Abstract][Full Text] [Related]
19. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
[TBL] [Abstract][Full Text] [Related]
20. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
